Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
Justus G Garweg1,21Swiss Eye Institute, Rotkreuz, and Berner Augenklinik Am Lindenhofspital, Bern, Switzerland; 2Department of Ophthalmology, Inselspital, University of Bern, Bern, SwitzerlandPurpose: To review published evidence for a treatment interval extension to ≥12-weeks in neovascular...
Guardado en:
Autor principal: | Garweg JG |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/261e998235554db1a3605447656a0880 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel PJ, et al.
Publicado: (2017) -
Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019) -
Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
por: Taipale C, et al.
Publicado: (2018) -
Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
por: Amoaku W, et al.
Publicado: (2018) -
Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes
por: Horner F, et al.
Publicado: (2021)